Scholars@Duke
Andrew Joseph Muir

Andrew Joseph Muir

Professor of Medicine
Medicine, Gastroenterology
andrew.muir@duke.edu
Duke Box 3913, Durham, NC 27710
03137B Hosp South, Durham, NC 27710

Selected Publications

Barriers and Strategies to Effective Serious Illness Communication for Patients with End-Stage Liver Disease in the Intensive Care Setting.

Journal Article J Intensive Care Med · September 9, 2024 Background: Patients with end-stage liver disease (ESLD) often require Intensive Care Unit (ICU) admission during the disease trajectory, but aggressive medical treatment has not resulted in increased quality of life for patients or caregivers. Methods: Th ... Full text Link to item Cite

Inadequate Dietary Education and Poor Adherence to a High Protein, Low Sodium Diet in Cirrhosis: Mixed Methods Approach.

Journal Article Dig Dis Sci · September 2024 BACKGROUND: Malnutrition in cirrhosis is associated with poor outcomes, leading to guidelines for a high protein, low sodium diet; however, there is no guidance regarding the implementation of diet education in clinical practice. METHODS: A mixed methods s ... Full text Link to item Cite

Psychological processes and alcohol reduction in patients with chronic hepatitis C: Results from the HepART trial.

Journal Article Alcohol Clin Exp Res (Hoboken) · August 2024 BACKGROUND: There is a lack of randomized controlled trials of behavioral interventions and process-level research related to alcohol reduction among patients with chronic liver disease (e.g., hepatitis C viral (HCV) infection). We conducted a process-leve ... Full text Link to item Cite

Decreased Completion of Ordered Laboratories and Imaging in Telehealth Compared With In-person Hepatology Encounters.

Journal Article J Clin Gastroenterol · July 16, 2024 OBJECTIVE: To evaluate order completion after telehealth compared with in-person encounters. BACKGROUND: Completion of ordered testing, including laboratories and imaging, is an important aspect of successful outpatient care of patients with liver disease. ... Full text Link to item Cite

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.

Journal Article Hepatol Commun · July 1, 2024 BACKGROUND: Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage and predict PSC-related fi ... Full text Link to item Cite

Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study.

Journal Article Am J Transplant · March 2024 Curative hepatitis C virus (HCV) therapy has increased transplantation from HCV-infected nucleic acid test-positive donors to HCV-uninfected recipients (D+/R-). We evaluated outcomes of early and late HCV treatment among D+/R- nonliver organ transplants. P ... Full text Link to item Cite

Characterization of social determinants of health of a liver transplant referral population.

Journal Article Liver Transpl · November 1, 2023 Disparities exist in referral and access to the liver transplant (LT) waitlist, and social determinants of health (SDOH) are increasingly recognized as important factors driving health inequities, including in LT. The SDOH of potential transplant candidate ... Full text Link to item Cite

Parental leave, childcare policies, and workplace bias for hepatology professionals: A national survey.

Journal Article Hepatol Commun · September 1, 2023 BACKGROUND: The presence of workplace bias around child-rearing and inadequate parental leave may negatively impact childbearing decisions and sex equity in hepatology. This study aimed to understand the influence of parental leave and child-rearing on car ... Full text Link to item Cite

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.

Journal Article Clin Gastroenterol Hepatol · June 2023 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a major unmet medical need in clinical hepatology. Cilofexor is a nonsteroidal farnesoid X receptor agonist being evaluated for the treatment of PSC. Here, we describe the safety and preliminary ef ... Full text Link to item Cite

Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.

Journal Article J Gastroenterol Hepatol · June 2023 BACKGROUND AND AIM: Staining for hepatitis B viral antigens is often done in liver biopsies from patients with chronic hepatitis B, but its correlates with clinical phenotypes are not well described. METHODS: Biopsies were collected from a large cohort of ... Full text Link to item Cite

Safety and yield of percutaneous liver biopsy in adults and children with chronic hepatitis B: Results from a prospective, multicenter study.

Journal Article Hepatol Commun · June 1, 2023 BACKGROUND: Prospective data regarding the safety and yield of liver biopsy in both adults and children with chronic hepatitis B are limited. The aim of this study is to report safety, yield, and complication rates among adults and children with chronic he ... Full text Link to item Cite

Consider hospice in end-stage liver disease prognostic scale to open discussions regarding six-month mortality.

Journal Article JGH Open · April 2023 BACKGROUND AND AIM: Hospice is underutilized in the management of patients with end-stage liver disease and may improve the patient experience at the end of life. This study aims to create a novel prognostic scale to accurately predict 6-month mortality to ... Full text Link to item Cite

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Journal Article Gut · March 2023 OBJECTIVE: In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confir ... Full text Link to item Cite

Performance of the Pooled Cohort Equations in non-alcoholic fatty liver disease: The Multi-Ethnic Study of Atherosclerosis.

Journal Article Liver Int · March 2023 BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with a high risk of cardiovascular disease. Whether risk scores developed in the general population accurately assess cardiovascular risk in the NAFLD population is unknown. This ... Full text Link to item Cite

Rates of employment after liver transplant: A nationwide cohort study.

Journal Article Hepatol Commun · March 1, 2023 BACKGROUND: Employment outcomes after liver transplant (LT) over the past decade have not been described. METHODS: LT recipients ages 18-65 from 2010-2018 were identified in Organ Procurement and Transplantation Network data. Employment within two years po ... Full text Link to item Cite

Evaluation of an Abnormal Liver Panel After Liver Transplantation.

Journal Article Clin Liver Dis · February 2023 Abnormal liver tests are common after liver transplantation. The differential diagnosis depends on the clinical context, particularly the time course, pattern and degree of elevation, and donor and recipient factors. The perioperative period has distinct c ... Full text Link to item Cite

Access to technology to support telehealth in areas without specialty care for liver disease.

Journal Article Hepatology · January 1, 2023 BACKGROUND AND AIMS: Telehealth may be a successful strategy to increase access to specialty care for liver disease, but whether the areas with low access to care and a high burden of liver-related mortality have the necessary technology access to support ... Full text Link to item Cite

Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis.

Journal Article Dig Dis Sci · December 2022 BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease, and many patients ultimately require liver transplantation (LT). PSC also confers an increased risk of malignancies, including cholangiocarcinoma (CCA) and colorectal ... Full text Link to item Cite

MELD-Na Accurately Predicts 6-Month Mortality in Patients With Decompensated Cirrhosis: Potential Trigger for Hospice Referral.

Journal Article J Clin Gastroenterol · November 2022 GOAL: The goal of this study was to determine the accuracy of Model of End-stage Liver Disease-Sodium (MELD-Na) in predicting 6-month mortality for patients listed for liver transplantation on the United Network of Organ Sharing (UNOS) waitlist. BACKGROUND ... Full text Link to item Cite

Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B.

Journal Article Hepatology · September 2022 BACKGROUND AND AIMS: Treatment of immune-tolerant (IT) children and adults with combined peginterferon alfa-2a and entecavir results in a decline in serum HBeAg and HBsAg concentrations but rarely results in loss of HBeAg or sustained off-treatment respons ... Full text Link to item Cite

Recent updates in preemptive transjugular intrahepatic portosystemic shunt for acute variceal bleeding.

Journal Article Clin Liver Dis (Hoboken) · September 2022 Content available: Author Interview and Audio Recording. ... Full text Link to item Cite

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.

Conference Hepatology · May 2022 BACKGROUND AND AIMS: Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver-related complications in patien ... Full text Link to item Cite

Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response.

Journal Article Clin Gastroenterol Hepatol · February 2022 BACKGROUND & AIMS: Achieving sustained virologic response (SVR) among patients with hepatitis C virus (HCV) leads to patient reported outcome (PRO) improvement. We aimed to assess the long-term post-SVR PRO trends in HCV patients with cirrhosis. METHODS: P ... Full text Link to item Cite

Racial and Socioeconomic Disparities in Utilization of Telehealth in Patients with Liver Disease During COVID-19.

Journal Article Dig Dis Sci · January 2022 BACKGROUND AND AIMS: The coronavirus disease 2019 (COVID-19) pandemic resulted in a rapid expansion of telehealth services in hepatology. However, known racial and socioeconomic disparities in internet access potentially translate into barriers for the use ... Full text Link to item Cite

Racial disparities in transjugular intrahepatic portosystemic shunt procedure outcomes.

Journal Article BMJ Open Gastroenterol · January 2022 OBJECTIVE: The transjugular intrahepatic portosystemic shunt (TIPS) procedure is an important intervention for management of complications of portal hypertension. The objective of this study was to identify predictors of mortality from the TIPS procedure w ... Full text Link to item Cite

A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.

Journal Article Hepatology · December 2021 BACKGROUND AND AIMS: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable. APPROACH AND RESULTS: We conducted a ... Full text Link to item Cite

Trends in statin utilisation in US adults with non-alcoholic fatty liver disease.

Journal Article Aliment Pharmacol Ther · December 2021 BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has high morbidity and mortality related to cardiovascular disease (CVD), but statins have been historically underutilised in these patients due to concern for hepatotoxicity. AIMS: To characterise tren ... Full text Link to item Cite

Care After Cure: Long-term Follow-up in Hepatitis C

Journal Article Current Hepatology Reports · December 1, 2021 Purpose of Review: To summarize recommendations and common practices for long-term surveillance after hepatitis C cure. Recent Findings: Patients with advanced fibrosis and cirrhosis have continued risk of the complications of portal hypertension and hepat ... Full text Cite

A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.

Journal Article Mol Genet Metab Rep · December 2021 INTRODUCTION: A deficiency of glycogen debrancher enzyme in patients with glycogen storage disease type III (GSD III) manifests with hepatic, cardiac, and muscle involvement in the most common subtype (type a), or with only hepatic involvement in patients ... Full text Open Access Link to item Cite

Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study.

Journal Article J Viral Hepat · November 2021 Hepatitis B e antigen (HBeAg) is a soluble viral protein in plasma of patients with hepatitis B virus infection. HBeAg loss is an important first stage of viral antigen clearance. We determined the rate and predictors of HBeAg loss in a North American coho ... Full text Link to item Cite

Adaptive Challenges and Family Support: Patient Self-Management during Treatment for Chronic Hepatitis C.

Journal Article Nurs Sci Q · October 2021 The authors describe a family's adaptive challenges and adaptive work during a family member's treatment for Chronic Hepatitis C. We audiorecorded index and final clinical visits and interviewed participants (patients and providers) following the visits. W ... Full text Link to item Cite

Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C.

Journal Article Dig Dis Sci · September 2021 BACKGROUND: Patients with chronic hepatitis C and risky/harmful alcohol use experience poor outcomes. Granular data evaluating whether alcohol counseling during hepatitis C treatment impacts longitudinal alcohol consumption are lacking. AIMS: To evaluate w ... Full text Link to item Cite

Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort.

Journal Article Clin Imaging · September 2021 PURPOSE: Proton pump inhibitor (PPI) use is a potential risk factor for hepatic encephalopathy (HE), but few studies have examined the effect on post-TIPS HE. The purpose of this study was to determine whether PPIs are associated with increased rates of po ... Full text Link to item Cite

Socioeconomic Status Is Associated with the Risk of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.

Journal Article J Vasc Interv Radiol · July 2021 PURPOSE: To determine whether socioeconomic status (SES) is associated with hepatic encephalopathy (HE) risk after transjugular intrahepatic portosystemic shunt (TIPS) creation. MATERIALS AND METHODS: This single-institution retrospective study included 36 ... Full text Link to item Cite

Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America.

Journal Article J Viral Hepat · July 2021 BACKGROUND: In chronic hepatitis B (CHB) viral infection, e antigen positivity (HBeAg+) is associated with high levels of viral replication and infectivity. Furthermore, HBeAg-positive CHB is associated with a liver disease spectrum ranging from none to se ... Full text Link to item Cite

Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.

Journal Article Clin Gastroenterol Hepatol · June 2021 BACKGROUND & AIMS: Serum alkaline phosphatase (ALP) and the enhanced liver fibrosis (ELF) score are used as endpoints in trials of patients with primary sclerosing cholangitis (PSC). We aimed to quantify inter- and intra-individual variation in levels of A ... Full text Link to item Cite

Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.

Journal Article Eur Radiol · June 2021 OBJECTIVES: The LI-RADS M (LR-M) category describes hepatic lesions probably or definitely malignant, but not specific for hepatocellular carcinoma in at-risk patients. Differentiation among LR-M entities, particularly detecting cholangiocarcinoma-containi ... Full text Link to item Cite

Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.

Journal Article Hepatology · June 2021 BACKGROUND AND AIMS: Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North Amer ... Full text Link to item Cite

Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives.

Journal Article J Viral Hepat · May 2021 Alcohol consumption in the setting of chronic HCV is associated with accelerated progression towards cirrhosis, increased risk of hepatocellular carcinoma and higher mortality. This analysis contextualizes how sociodemographic factors, chronic pain and dep ... Full text Link to item Cite

A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.

Journal Article Hepatology · March 2021 BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a heterogeneous cholangiopathy characterized by progressive biliary fibrosis. RNA sequencing of liver tissue from patients with PSC (n = 74) enrolled in a 96-week clinical trial was performed to ... Full text Link to item Cite

Coordination, Cost, and Changing Epidemiology-Considerations in the Hepatitis C Care Cascade.

Journal Article Hepatol Commun · March 2021 This editorial reviews two articles in hepatology communications addressing challenges in the hepatitis C care cascade. ... Full text Link to item Cite

Change in Alcohol Use and Association with Positive and Negative Emotions: Results from an Alcohol Treatment Study with Hepatitis C Patients.

Journal Article Alcohol Treat Q · 2021 Few studies exist on the change over time in positive and negative emotions during treatment for alcoholism disorders. We aimed to evaluate relationship between alcohol reduction and change in positive and negative emotions. Chronic HCV patients (n=174) wi ... Full text Link to item Cite

Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do?

Journal Article J Infect Dis · November 27, 2020 The opioid epidemic has resulted in an increase in organ donors with hepatitis C virus (HCV) infection in the United States. With the development of direct-acting antiviral regimens that offer high sustained virologic response rates even in the setting of ... Full text Link to item Cite

Impact of Malnutrition on Outcomes in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Insertion.

Journal Article Dig Dis Sci · November 2020 BACKGROUND: Malnutrition is common in patients with cirrhosis and is associated with poor outcomes after hepatic resection and liver transplantation. Transjugular intrahepatic portosystemic shunt (TIPS) is performed for complications of cirrhosis. AIM: To ... Full text Link to item Cite

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.

Journal Article Clin Gastroenterol Hepatol · October 2020 BACKGROUND & AIMS: The direct-acting antiviral combination glecaprevir/pibrentasvir has been approved by the Food and Drug Administration for 8 weeks of treatment in treatment-naïve patients with hepatitis C virus (HCV) infection without cirrhosis or with ... Full text Link to item Cite

Use of Skeletal Muscle Index as a Predictor of Wait-List Mortality in Patients With End-Stage Liver Disease.

Conference Liver Transpl · September 2020 The aim of this study is to validate a proposed definition of sarcopenia in predicting wait-list mortality. We retrospectively evaluated 355 adults (age ≥18 years) with cirrhosis listed for first-time LT from January 1, 2010, to April 1, 2018 from our cent ... Full text Link to item Cite

A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection.

Journal Article Hepatology · June 2020 BACKGROUND AND AIMS: Hepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions. APPROACH AND RESULTS: A total of 181 patients w ... Full text Link to item Cite

Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C.

Journal Article Transplantation · June 2020 BACKGROUND: Patients with nonalcoholic steatohepatitis (NASH) are waitlisted at older ages than individuals with other liver diseases, but the effect of age on liver transplantation (LT) outcomes in this population and whether it differs from other etiolog ... Full text Link to item Cite

Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence.

Journal Article Aliment Pharmacol Ther · June 2020 BACKGROUND: Direct-acting anti-virals (DAA) are highly effective for hepatitis C virus (HCV) treatment, but perceived risks of medication non-adherence may restrict access to care. Digital medicine programme (DMP) has improved adherence and outcomes for so ... Full text Link to item Cite

A Big Step Forward in Hepatitis C Screening.

Journal Article Clin Liver Dis (Hoboken) · April 2020 http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/15-4-reading-kapila a video presentation of this article. ... Full text Link to item Cite

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.

Journal Article J Hepatol · March 2020 BACKGROUND & AIMS: Direct-acting antiviral (DAA) therapy for HCV has high efficacy and limited toxicity. We hypothesised that the efficacy of glecaprevir-pibrentasvir for chronic HCV with a simplified treatment monitoring schedule would be non-inferior to ... Full text Link to item Cite

Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes.

Journal Article Clin Infect Dis · February 3, 2020 BACKGROUND: The causative relationship between the clearance of infections and long-term, health-related quality-of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted. The aim of this study was to assess long-term ... Full text Link to item Cite

Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.

Journal Article Clin Gastroenterol Hepatol · February 2020 BACKGROUND & AIMS: Patients with hepatitis C virus (HCV) infections who achieve a sustained virologic response (SVR) to treatment have improved patient-reported outcomes (PROs). We compared post-treatment PRO scores between patients with chronic HCV infect ... Full text Link to item Cite

Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.

Journal Article Curr HIV/AIDS Rep · February 2020 PURPOSE OF REVIEW: The prevalence of Hepatitis C virus (HCV) in the US incarcerated population is disproportionately high, and when inmates with infection are released back into the general population, they play a substantial role in the spread of disease. ... Full text Link to item Cite

Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.

Journal Article JHEP Rep · February 2020 BACKGROUND & AIMS: A DNA methylation (DNAm) signature derived from 353 CpG sites (the Horvath clock) has been proposed as an epigenetic measure of chronological and biological age. This epigenetic signature is accelerated in diverse tissue types in various ... Full text Link to item Cite

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.

Journal Article Hepatology · December 2019 Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridging fi ... Full text Link to item Cite

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Journal Article Clin Gastroenterol Hepatol · November 2019 BACKGROUND & AIMS: The incidence and outcomes of alanine aminotransferase (ALT) flares during the natural history of chronic HBV infection has not been determined in a large, racially heterogeneous group of patients in North America. METHODS: We collected ... Full text Link to item Cite

Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.

Journal Article Am J Gastroenterol · October 2019 INTRODUCTION: Although there is substantial evidence suggesting poor health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC), similar data in nonalcoholic steatohepatitis (NASH) have not been fully assessed. The aim is to compare H ... Full text Link to item Cite

1089 Hypophosphatemia in Patients With Alcoholic Hepatitis

Conference American Journal of Gastroenterology · October 2019 INTRODUCTION:Patients with alcoholic hepatitis suffer from high rates of malnutrition and are at risk for hypophosphatemia due to poor dietary intake, renal wasting, and refeeding syndrom ... Full text Cite

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.

Journal Article Hepatology · September 2019 Primary sclerosing cholangitis (PSC) represents a major unmet medical need. In a phase II double-blind, placebo-controlled study, we tested the safety and efficacy of cilofexor (formerly GS-9674), a nonsteroidal farnesoid X receptor agonist in patients wit ... Full text Link to item Cite

N-Acetylcysteine in the Management of Acute Liver Failure From Sickle Cell Hepatic Crisis.

Journal Article ACG Case Rep J · August 2019 N-acetylcysteine (NAC) has been well studied in the treatment of acetaminophen-induced and select non-acetaminophen-induced liver failure. However, its role in the management of sickle cell hepatic crisis resulting in acute liver failure (ALF) is unknown. ... Full text Link to item Cite

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.

Journal Article J Viral Hepat · July 2019 Hepatitis B e antigen (HBeAg) is an important serological marker of hepatitis B virus (HBV) infection and is associated with higher levels of viraemia, increased risk of infectivity to others and increased risk of hepatocellular carcinoma. We analysed HBeA ... Full text Link to item Cite

HCV Exposure in the Health Care Arena. Is there a Role for Post-exposure Prophylaxis?

Journal Article Current Hepatology Reports · June 15, 2019 Purpose of Review: Healthcare workers are a vulnerable population for exposure to a variety of bloodborne pathogens including hepatitis C (HCV). With the development of novel efficacious treatments for chronic HCV, the role of post-exposure prophylaxis (PE ... Full text Cite

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

Journal Article J Hepatol · March 2019 BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver disease devoid of effective medical intervention. NGM282, an engineered, non-tumorigenic FGF19 analogue, potently regulates CYP7A1-medi ... Full text Link to item Cite

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.

Journal Article Hepatology · February 2019 Lysyl oxidase like-2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC). We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody directed against LOXL2 ... Full text Link to item Cite

Clinical Encounters and Treatment Initiation for Chronic Hepatitis C Patients: Applications of Adaptive Leadership Framework for Chronic Illness.

Journal Article Sage Open · 2019 Chronic Hepatitis C (CHC) is the most common blood-borne infection in the U. S. Patients with CHC undergoing treatment face many challenges including adherence to medications and management of symptoms; health care practitioners are well positioned to faci ... Full text Link to item Cite

Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy.

Journal Article N C Med J · 2019 Prisoners in the United States are disproportionately affected by hepatitis C. Addressing the disease behind bars is crucial for curtailing the epidemic in the greater population. Effective strategies for testing and treatment are elucidated here. Recommen ... Full text Link to item Cite

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.

Journal Article J Hepatol · December 2018 BACKGROUND & AIMS: Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogen ... Full text Link to item Cite

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.

Journal Article Gastroenterology · October 2018 BACKGROUND & AIMS: Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients with adv ... Full text Link to item Cite

The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis.

Journal Article Clin Transplant · October 2018 Human leukocyte antigen (HLA) serotyping is not considered to have significant impact on liver graft survival and does not factor into U.S. organ allocation. Immune-related liver diseases such as primary sclerosing cholangitis (PSC), autoimmune hepatitis ( ... Full text Link to item Cite

TIPS Outcomes According to Race and Ethnicity

Conference AMERICAN JOURNAL OF GASTROENTEROLOGY · October 1, 2018 Link to item Cite

The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.

Journal Article Contemp Clin Trials · September 2018 INTRODUCTION: Among patients with hepatitis C virus (HCV) infection, alcohol synergistically increases the risk of cirrhosis, hepatocellular carcinoma, and death. Randomized controlled trials of integrated models of HCV-alcohol treatment have been recommen ... Full text Link to item Cite

NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Journal Article Hepatol Commun · September 2018 Patients with primary biliary cholangitis (PBC) who had an inadequate response to ursodiol have few treatment options. Alkaline phosphatase (ALP) and bilirubin levels correlate with the risk of liver transplant or death in PBC patients. Fibroblast growth f ... Full text Link to item Cite

Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.

Conference Hepatology · July 2018 UNLABELLED: Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC-specific patie ... Full text Link to item Cite

Improving Hepatitis C Identification: Technology Alone Is Not the Answer.

Journal Article Health Promot Pract · July 2018 An estimated 3 to 5 million Americans are chronically infected with hepatitis C virus (HCV), and approximately 75% of those persons were born between 1945 and 1965 (the so-called baby boomer generation). Because of the largely asymptomatic nature of HCV, u ... Full text Link to item Cite

Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.

Journal Article Expert Opin Pharmacother · April 2018 INTRODUCTION: Direct acting antivirals (DAA's) have revolutionized the treatment of hepatitis C (HCV). However, questions persist concerning their efficacy in minority populations. AREAS COVERED: In this review, the authors review outcomes for treatment of ... Full text Link to item Cite

Hepatocellular Carcinoma Surveillance.

Journal Article Clin Gastroenterol Hepatol · January 2018 Full text Link to item Cite

Diagnosing Liver Fibrosis and Cirrhosis: Serum, Imaging, or Tissue?

Journal Article Clin Gastroenterol Hepatol · January 2018 Full text Link to item Cite

Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.

Journal Article Open Forum Infect Dis · January 2018 BACKGROUND: Direct-acting antivirals (DAA) as curative therapy for hepatitis C virus (HCV) infection offer >95% sustained virologic response (SVR), including in patients with human immunodeficiency virus (HIV) infection. Despite improved safety and efficac ... Full text Open Access Link to item Cite

Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.

Journal Article Dig Dis Sci · November 2017 BACKGROUND: There is increasing evidence for a heterogeneity of phenotypes in primary sclerosing cholangitis (PSC), but differences across the age spectrum in adults with PSC have not been well characterized. AIMS: To characterize phenotypic variations and ... Full text Link to item Cite

Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5.

Journal Article J Magn Reson Imaging · September 2017 PURPOSE: To identify demographic and imaging features in magnetic resonance imaging (MRI) that are associated with upgrade of Liver Imaging Reporting and Data System (LI-RADS) category 4 (LR-4) observations to category 5 (LR-5), and to assess their effects ... Full text Link to item Cite

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

Journal Article J Hepatol · August 2017 BACKGROUND & AIMS: Hepatitis C virus (HCV) therapy that is highly efficacious, pangenotypic, with a high barrier to resistance and short treatment duration is desirable. The efficacy and safety of 8- and 12-week treatments with glecaprevir (ABT-493; NS3/4A ... Full text Link to item Cite

Complementary and Alternative Medicine Use in United States Adults With Liver Disease.

Journal Article J Clin Gastroenterol · July 2017 GOALS: To describe the complementary and alternative medicine (CAM) use in US adults with liver disease. BACKGROUND: The prevalence and patterns of CAM use among US adults with liver disease have not been well characterized. The 2012 National Health Interv ... Full text Link to item Cite

Outcomes of liver retransplantation in patients with primary sclerosing cholangitis.

Journal Article Liver Transpl · June 2017 Liver retransplantation in patients with primary sclerosing cholangitis (PSC) has not been well studied. The aims of this study were to characterize patients with PSC listed for and undergoing retransplantation and to describe the outcomes in these patient ... Full text Link to item Cite

American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.

Journal Article Gastroenterology · May 2017 Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic liver disease, are a leading cause of morbidity and mortality globally. Early identification of patients with cirrhosis at high ... Full text Link to item Cite

Randomized trial of an uncertainty self-management telephone intervention for patients awaiting liver transplant.

Journal Article Patient Educ Couns · March 2017 OBJECTIVE: We tested an uncertainty self-management telephone intervention (SMI) with patients awaiting liver transplant and their caregivers. METHODS: Participants were recruited from four transplant centers and completed questionnaires at baseline, 10, a ... Full text Link to item Cite

Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.

Journal Article Transpl Int · February 2017 This prospective, randomized, phase 2 study in subjects with recurrent hepatitis C virus (HCV) genotype 1 postorthotopic liver transplant evaluated once-daily simeprevir 150 mg + sofosbuvir 400 mg, with and without ribavirin 1000 mg. Primary endpoint was p ... Full text Link to item Cite

Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.

Journal Article Annu Rev Med · January 14, 2017 The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of ... Full text Link to item Cite

Treatment of Hepatitis C

Chapter · January 1, 2017 Full text Cite

Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.

Journal Article Curr Hepatol Rep · December 2016 Chronic hepatitis C virus (HCV) infection is burdensome in patients with chronic kidney disease and contributes to substantial liver-related and all-cause morbidity and mortality. HCV infection itself may cause kidney dysfunction, as exemplified through mi ... Full text Link to item Cite

Mechanisms of Ascites Development-Reply.

Journal Article JAMA · November 1, 2016 Full text Link to item Cite

Significant Morbidity and Mortality Among Hospitalized End-Stage Liver Disease Patients in Medicare.

Journal Article J Pain Symptom Manage · September 2016 CONTEXT: For end-stage liver disease (ESLD) patients, care focuses on managing the life-threatening complications of portal hypertension, causing high resource utilization. OBJECTIVES: To describe the end-of-life trajectory of hospitalized ESLD patients in ... Full text Link to item Cite

Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease.

Journal Article Open Forum Infect Dis · September 2016 Background.  Hepatitis C virus (HCV) infection is a leading cause of cirrhosis and the primary cause of liver transplantation in the United States, and coinfection with human immunodeficiency virus (HIV) increases the risk of comorbidities. However, health ... Full text Open Access Link to item Cite

Natural history of liver imaging reporting and data system category 4 nodules in MRI.

Journal Article Abdom Radiol (NY) · September 2016 PURPOSE: The purpose of this study was to characterize the MR imaging features and outcomes of liver imaging reporting and data system (LI-RADS) category 4 (LR4) nodules, with an emphasis on upgrade to category 5 (LR5) and development of contraindications ... Full text Link to item Cite

Evaluation of New-Onset Ascites.

Journal Article JAMA · July 19, 2016 Full text Link to item Cite

Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation.

Journal Article Liver Transpl · July 2016 Despite major improvements in access to liver transplantation (LT), disparities remain. Little is known about how distrust in medical care, patient preferences, and the origins shaping those preferences contribute to differences surrounding access. We perf ... Full text Open Access Link to item Cite

Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.

Journal Article Hepatology · February 2016 UNLABELLED: Black patients chronically infected with genotype 1 hepatitis C virus (HCV) have historically had lower rates of response to interferon-based treatment than patients of other races. In the phase 3 ION program, the single-tablet regimen of the N ... Full text Open Access Link to item Cite

A Systematic Review of Race and Ethnicity in Hepatitis C Clinical Trial Enrollment.

Journal Article J Natl Med Assoc · February 2016 The African American/Black population in the United States (US) is disproportionately affected by hepatitis C virus (HCV) and has lower response rates to current treatments. This analysis evaluates the participation of African American/Blacks in North Amer ... Full text Open Access Link to item Cite

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Journal Article Gastroenterology · February 2016 BACKGROUND & AIMS: The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate th ... Full text Link to item Cite

Integrating daclatasvir into hepatitis c therapy.

Journal Article Clin Liver Dis (Hoboken) · January 2016 Full text Link to item Cite

Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level.

Journal Article Public Health Rep · 2016 OBJECTIVES: The national Viral Hepatitis Action Plan recommends strengthening partnerships among health departments, community-based organizations, and health-care providers for hepatitis services. We implemented a hepatitis C virus (HCV) testing and linka ... Full text Link to item Cite

State of the State in Gastroenterology.

Journal Article N C Med J · 2016 Gastrointestinal disorders range from life-threatening conditions to benign disorders, but all can impact the daily life of millions of Americans. For colorectal cancer, liver disease, and other conditions, early identification is important to avoid late-s ... Full text Link to item Cite

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Journal Article N Engl J Med · December 31, 2015 BACKGROUND: As the population that is infected with the hepatitis C virus (HCV) ages, the number of patients with decompensated cirrhosis is expected to increase. METHODS: We conducted a phase 3, open-label study involving both previously treated and previ ... Full text Link to item Cite

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

Journal Article Clin Gastroenterol Hepatol · November 2015 The recent advances in hepatitis C virus (HCV) therapeutics have brought combinations of direct acting antiviral medications that offer interferon-free, well-tolerated regimens with sustained virologic response rates greater than 90% in clinical trials for ... Full text Link to item Cite

Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes.

Journal Article Ther Adv Chronic Dis · November 2015 The burden of chronic hepatitis C virus (HCV) infection is significant and growing. HCV is considered one of the leading causes of liver disease worldwide and the leading cause of liver transplantation globally. While those infected is estimated in the hun ... Full text Open Access Link to item Cite

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Journal Article Gastroenterology · September 2015 BACKGROUND & AIMS: There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. METHODS: In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, t ... Full text Link to item Cite

PharmGKB summary: peginterferon-α pathway.

Journal Article Pharmacogenet Genomics · September 2015 Full text Link to item Cite

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.

Journal Article Hepatology · August 2015 UNLABELLED: Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. In this study, we sought to better ... Full text Link to item Cite

Understanding the Complexities of Cirrhosis.

Journal Article Clin Ther · August 2015 PURPOSE: Cirrhosis and its related complications remain a prominent global health concern despite advances in understanding and treating the disorder. Early diagnosis and intervention strategies may reduce the impact of cirrhosis; however, it can be diffic ... Full text Link to item Cite

Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

Journal Article J Gastroenterol Hepatol · August 2015 BACKGROUND AND AIM: Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus (HCV) infection and cirrhosis, although it can also be observed in patients without cirrhosis by a virus-mediated phenomenon. This study assessed the pre ... Full text Link to item Cite

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

Journal Article JAMA · May 5, 2015 IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE: To determine the rates of sustained virologic response (SVR) in pati ... Full text Link to item Cite

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

Journal Article JAMA · May 5, 2015 IMPORTANCE: Effective and well-tolerated, interferon-free regimens are needed for treatment of patients with chronic hepatitis C virus (HCV) infection and cirrhosis. OBJECTIVE: All-oral therapy with daclatasvir (nonstructural protein 5A [NS5A] inhibitor), ... Full text Link to item Cite

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

Journal Article J Clin Gastroenterol · April 2015 BACKGROUND: The phase 3 studies of telaprevir (T) in combination with peginterferon α-2a and ribavirin (PR) in treatment-naive genotype 1 chronic hepatitis C virus-infected patients (ADVANCE/ILLUMINATE) were not designed a priori to assess the effect of ra ... Full text Link to item Cite

Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals.

Journal Article Open Forum Infect Dis · April 2015 We evaluated the impact of antiretroviral-induced dyslipidemia on hepatitis C virus (HCV) biogenesis in human immunodeficiency virus (HIV)/HCV coinfected patients. This study used serum samples from antiretroviral-naive HIV/HCV patients initiating their fi ... Full text Open Access Link to item Cite

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

Journal Article J Hepatol · February 2015 BACKGROUND & AIMS: The safety profiles of boceprevir and telaprevir in the treatment of chronic hepatitis C, administered in academic and community centres across the United States, were evaluated. METHODS: In 90 medical centres, patients with chronic HCV ... Full text Link to item Cite

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.

Journal Article Gastroenterology · January 2015 BACKGROUND & AIMS: Interferon alfa-based regimens used to treat recurrent hepatitis C virus (HCV) infection after liver transplantation are poorly tolerated, associated with generally modest efficacy, and can interact with immunosuppressive agents. We eval ... Full text Link to item Cite

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Journal Article J Hepatol · December 2014 BACKGROUND & AIMS: Peginterferon lambda-1a (Lambda) is a type-III interferon with similar antiviral activity to alfa interferons but with a diminished extrahepatic receptor distribution, reducing the risk for extrahepatic adverse events. METHODS: This was ... Full text Link to item Cite

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Journal Article N Engl J Med · May 15, 2014 BACKGROUND: High rates of sustained virologic response were observed among patients with hepatitis C virus (HCV) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor ledipasvir. T ... Full text Link to item Cite

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Journal Article N Engl J Med · May 15, 2014 BACKGROUND: In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of sustained virologic response among previously untreated patients with hepa ... Full text Link to item Cite

The rapid evolution of treatment strategies for hepatitis C.

Journal Article Am J Gastroenterol · May 2014 Hepatitis C virus (HCV) treatment took a major step forward at the end of 2013 with the approvals of the second-generation protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi). The interferon-free regimen of s ... Full text Link to item Cite

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Journal Article N Engl J Med · April 17, 2014 BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. METHODS: We conducted a phase 3, randomized, op ... Full text Link to item Cite

Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.

Journal Article J Hepatol · April 2014 BACKGROUND & AIMS: Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribav ... Full text Link to item Cite

Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

Journal Article Clin Infect Dis · April 2014 BACKGROUND: Myelosuppression due to pegylated interferon (peg-IFN) is common during treatment for hepatitis C virus. The relationship between infection risk and decreases in leukocyte lines, however, is not well established. The objective of this analysis ... Full text Link to item Cite

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Journal Article Clin Pharmacol Ther · February 2014 Pegylated interferon-α (PEG-IFN-α or PEG-IFN 2a and 2b)- and ribavirin (RBV)-based regimens are the mainstay for treatment of hepatitis C virus (HCV) genotype 1. IFNL3 (IL28B) genotype is the strongest baseline predictor of response to PEG-IFN-α and RBV th ... Full text Link to item Cite

Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.

Journal Article Top Antivir Med · 2014 Treatment of hepatitis C virus (HCV)-infected patients with cirrhosis remains challenging. Biopsy to stage liver fibrosis remains the standard for identifying cirrhosis, although the noninvasive technique of transient elastography is promising in this rega ... Link to item Cite

Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.

Journal Article PLoS One · 2014 AIM: Sustained virologic response (SVR) can be attained with boceprevir plus peginterferon alfa and ribavirin (PR) in up to 68% of patients, and short duration therapy is possible if plasma HCV RNA levels are undetectable at treatment week 8 (TW8 response) ... Full text Link to item Cite

Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.

Journal Article J Viral Hepat · December 2013 Anaemia frequently complicates peginterferon/ribavirin therapy for chronic hepatitis C infection. Better prediction of anaemia, ribavirin dose reduction or erythropoietin (EPO) need, may enhance patient management. Inosine triphosphatase (ITPA) genetic var ... Full text Link to item Cite

Predictors of consent to pharmacogenomics testing in the IDEAL study.

Conference Pharmacogenet Genomics · November 2013 INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon ... Full text Link to item Cite

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Journal Article J Viral Hepat · November 2013 Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in ... Full text Link to item Cite

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

Journal Article Lancet Infect Dis · May 2013 BACKGROUND: Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuvir, a uridine ... Full text Link to item Cite

IL28B in the era of direct-acting antivirals for hepatitis C.

Journal Article J Clin Gastroenterol · March 2013 The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and bocepr ... Full text Link to item Cite

Multiphase multi-detector row computed tomography in the setting of chronic liver disease and orthotopic liver transplantation: can a series be eliminated in order to reduce radiation dose?

Journal Article J Comput Assist Tomogr · 2013 OBJECTIVE: The objectives of this study were to explore utilization of multi-detector row computed tomography (MDCT) in screening for hepatocellular carcinoma (HCC) and to modify a liver CT protocol with a goal of dose reduction. METHODS: An electronic mai ... Full text Link to item Cite

Analysis of site performance in academic-based and community-based centers in the IDEAL Study.

Journal Article J Clin Gastroenterol · 2013 GOALS: To evaluate differences in metrics of quality and site performance in academic and community sites participating in a multicenter study. BACKGROUND: In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Ther ... Full text Link to item Cite

Hepatitis C

Journal Article Annals of Internal Medicine · December 10, 2012 Cite

In the clinic. Hepatitis C.

Journal Article Ann Intern Med · December 4, 2012 Full text Link to item Cite

Approach to the treatment-naïve patient with HCV genotype 1 infection.

Journal Article Infect Dis Clin North Am · December 2012 In May 2011, the protease inhibitors boceprevir and telaprevir were approved in combination with peginterferon-α and ribavirin for the treatment of genotype 1 chronic hepatitis C virus infection in the United States. These regimens brought substantial impr ... Full text Link to item Cite

Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection.

Journal Article AIDS Patient Care STDS · September 2012 Abstract Health care utilization for HIV-1-infected patients appears to be declining in the United States as a result of highly active antiviral therapy (HAART); yet the opposite appears true in the HIV/hepatitis C virus (HCV) coinfected population. The re ... Full text Link to item Cite

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.

Journal Article Dig Dis Sci · August 2012 BACKGROUND: Single-nucleotide polymorphisms (SNPs) in the IL28B and PNPLA3 gene regions have been associated with hepatic steatosis in genotype 1 (G1) chronic HCV infection but their clinical impacts remain to be determined. AIM: We sought to validate thes ... Full text Link to item Cite

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Journal Article Hepatology · August 2012 UNLABELLED: Recent studies have shown that a single-nucleotide polymorphism upstream of the interleukin-28B (IL28B) gene plays a major role in predicting therapeutic response in hepatitis C virus (HCV)-infected patients treated with pegylated interferon (P ... Full text Link to item Cite

Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.

Journal Article Hepatology · July 2012 UNLABELLED: Hepatitis C virus (HCV) subverts host cholesterol metabolism for key processes in its lifecycle. How this interference results in the frequently observed, genotype-dependent clinical sequelae of hypocholesterolemia, hepatic steatosis, and insul ... Full text Link to item Cite

Overcoming barriers to care for hepatitis C.

Journal Article N Engl J Med · June 28, 2012 Full text Link to item Cite

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.

Journal Article J Viral Hepat · May 2012 Low-density lipoprotein cholesterol (LDL-C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to peginterferon/ribavirin (pegIFN/RBV) for chronic hepatitis C (CHC) infection. IL28B has been linked with LDL-C ... Full text Link to item Cite

Surgical clearance for the patient with chronic liver disease.

Journal Article Clin Liver Dis · May 2012 Patients with chronic liver disease face greater risk of perioperative morbidity and mortality, with the greatest risk among patients with cirrhosis. Both the Child-Pugh score and the Model for End-Stage Liver Disease have been evaluated as predictors of p ... Full text Link to item Cite

An integrated alcohol abuse and medical treatment model for patients with hepatitis C.

Journal Article Dig Dis Sci · April 2012 BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment. AIMS: This prospective cohort study examined the feasibi ... Full text Open Access Link to item Cite

The horizon: New targets and new agents.

Journal Article Clin Liver Dis (Hoboken) · February 2012 Full text Link to item Cite

Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.

Journal Article J Hepatol · February 2012 BACKGROUND & AIMS: Interferon-alfa (IFN)-related cytopenias are common and may be dose-limiting. We performed a genome wide association study on a well-characterized genotype 1 HCV cohort to identify genetic determinants of peginterferon-α (pegIFN)-related ... Full text Link to item Cite

The genetics of virologic response

Chapter · January 1, 2012 The likelihood of response for an individual patient treated with standard pegylated interferon alpha and ribavirin for hepatitis C is impacted by a combination of viral factors and patient factors. Infection with viral genotypes 2 or 3 is favorable for re ... Full text Cite

Mixed model analysis of censored longitudinal data with flexible random-effects density.

Journal Article Biostatistics · January 2012 Mixed models are commonly used to represent longitudinal or repeated measures data. An additional complication arises when the response is censored, for example, due to limits of quantification of the assay used. While Gaussian random effects are routinely ... Full text Link to item Cite

Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.

Journal Article Value Health · 2012 BACKGROUND: Shortened courses of treatment with pegylated interferon alfa and ribavirin for patients with hepatitis C virus infection who experience rapid virologic response can be effective in appropriately selected patients. The cost-effectiveness of tru ... Full text Link to item Cite

Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.

Journal Article Antivir Ther · 2012 In 2011, the protease inhibitors boceprevir and telaprevir were approved in the United States and European Union for the treatment of hepatitis C infection. While remarkably effective, the newly approved therapies are also accompanied by additional side ef ... Full text Link to item Cite

IL28B: Implications for clinical practice

Journal Article Current Hepatitis Reports · January 1, 2012 The discovery of genetic variants near the gene for IL28B has provided new insight into the biology of hepatitis C infection and response to treatment with pegylated interferon alpha and ribavirin. Patients that carry the favorable CC genotype for SNP rs12 ... Full text Cite

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.

Journal Article J Hepatol · December 2011 BACKGROUND & AIMS: IL28B polymorphisms have been associated with both treatment induced and spontaneous clearance of hepatitis C virus (HCV). We previously found that LDL cholesterol levels were higher in chronic hepatitis C (CHC) patients with the CC geno ... Full text Link to item Cite

Telaprevir for the treatment of chronic hepatitis C infection.

Journal Article Expert Rev Anti Infect Ther · December 2011 Telaprevir is an NS3/4A protease inhibitor that has recently received US FDA approval for the treatment of chronic HCV infection. Telaprevir is given in combination with peg-IFN-α and ribavirin and is indicated for both treatment-naive and treatment-experi ... Full text Link to item Cite

HCV and Racial Differences

Journal Article · November 3, 2011 Full text Cite

An interrupted time series evaluation of a hepatitis C intervention for persons with HIV.

Journal Article AIDS Behav · November 2011 Accurate HCV knowledge is lacking among high-risk groups, including people with HIV/AIDS (PLWHA). Liver disease primarily due to HCV has emerged as a serious cause of mortality among PLWHA. We used an Interrupted Time Series design to evaluate a social-eco ... Full text Link to item Cite

Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.

Journal Article Hepatology · November 2011 Featured Publication UNLABELLED: Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment. This study evaluated the safety and efficacy of telaprevir-based ... Full text Link to item Cite

Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.

Journal Article Gastroenterol Clin North Am · September 2011 The HCV viral life cycle provides targets for drug development at virtually every step, and many new drugs aimed at these targets are currently being developed. Clinical practice takes a major step forward this year with the arrival of telaprevir and bocep ... Full text Link to item Cite

Racial differences in hepatitis C treatment eligibility.

Journal Article Hepatology · July 2011 UNLABELLED: Black Americans are disproportionally infected with hepatitis C virus (HCV) and are less likely than whites to respond to treatment with peginterferon (PEG-IFN) plus ribavirin (RBV). The impact of race on HCV treatment eligibility is unknown. W ... Full text Link to item Cite

Telaprevir for previously untreated chronic hepatitis C virus infection.

Journal Article N Engl J Med · June 23, 2011 BACKGROUND: In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the ... Full text Link to item Cite

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial.

Journal Article J Viral Hepat · April 2011 Featured Publication Previous studies of chronic hepatitis C virus (HCV) treatment have demonstrated variations in response among racial and ethnic groups including poorer efficacy rates among African American and Hispanic patients. The individualized dosing efficacy vs flat d ... Full text Link to item Cite

Boceprevir for untreated chronic HCV genotype 1 infection.

Journal Article N Engl J Med · March 31, 2011 BACKGROUND: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV- ... Full text Link to item Cite

Direct-acting antiviral medications for chronic hepatitis C virus infection.

Journal Article Gastroenterol Hepatol (N Y) · March 2011 Treatment of hepatitis C virus has traditionally been difficult because of low rates of treatment success and high rates of treatment discontinuation due to side effects. Current standard therapy consists of pegylated interferon α and ribavirin, both of wh ... Link to item Cite

IL28B polymorphisms and treatment of hepatitis C

Journal Article Current Hepatitis Reports · March 1, 2011 Recently, single-nucleotide polymorphisms near the IL28B gene have been identified as important in predicting treatment response and spontaneous clearance of the hepatitis C virus (HCV). In the less than 12 months since the initial genetic discoveries, our ... Full text Cite

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

Journal Article Hepatology · February 2011 UNLABELLED: Two functional variants in the inosine triphosphatase (ITPA) gene causing inosine triphosphatase (ITPase) deficiency protect against ribavirin (RBV)-induced hemolytic anemia and the need for RBV dose reduction in patients with genotype 1 hepati ... Full text Link to item Cite

Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center.

Journal Article Dig Dis Sci · December 2010 Featured Publication OBJECTIVES: The treatment of choice for HCC with cirrhosis is liver transplantation (LT). We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, an ... Full text Link to item Cite

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

Journal Article Hepatology · October 2010 UNLABELLED: Ribavirin-induced hemolytic anemia can prompt dose reductions and lower sustained virologic response (SVR) rates in the treatment of patients with chronic hepatitis C. The study aimed to determine if weight-based dosing of taribavirin (TBV), an ... Full text Link to item Cite

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Journal Article Gastroenterology · October 2010 BACKGROUND & AIMS: In a genome-wide association study of patients being treated for chronic hepatitis C, 2 functional variants in ITPA that cause inosine triphosphatase (ITPase) deficiency were shown to protect against ribavirin (RBV)-induced hemolytic ane ... Full text Link to item Cite

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.

Journal Article Gastroenterology · October 2010 BACKGROUND & AIMS: The current standard of care for patients with chronic hepatitis C virus (HCV) genotype 1 is once-weekly pegylated interferon-α (Peg-IFNα) plus daily ribavirin for 48 weeks. We evaluated the efficacy/safety of albinterferon alfa-2b (albI ... Full text Link to item Cite

Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue.

Journal Article Res Nurs Health · October 2010 We identified trajectories of illness uncertainty in chronic hepatitis C patients and examined their association with fatigue levels during 12 months of disease monitoring without treatment (watchful waiting). Sixty-two men and 63 women completed uncertain ... Full text Link to item Cite

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Journal Article Hepatology · September 2010 Featured Publication UNLABELLED: Interferon lambda 1 (IFN-lambda1) is a type III IFN that produces intracellular responses similar to those of IFN-alpha but in fewer cell types because of differences in the receptor distribution pattern, and this could potentially result in an ... Full text Link to item Cite

Development of fatal acute liver failure in HIV-HBV coinfected patients.

Journal Article World J Gastroenterol · August 28, 2010 Coinfection with hepatitis B virus (HBV) is not uncommon in human immunodeficiency virus (HIV)-infected individuals and patients with HIV-HBV coinfection are at high risk for progression of liver disease. Current guidelines regarding the treatment of HIV i ... Full text Link to item Cite

The use of complementary and alternative medicine by patients with chronic hepatitis C.

Journal Article Complement Ther Clin Pract · August 2010 BACKGROUND: The use of complementary and alternative medicine (CAM) is expanding globally. However, prevalence of its use by patients with chronic hepatitis C (CHC) remains unclear. METHODS: An exploratory, descriptive study was conducted using a questionn ... Full text Link to item Cite

Gastroesophageal reflux and altered motility in lung transplant rejection.

Journal Article Neurogastroenterol Motil · August 2010 BACKGROUND: Lung transplantation has become an effective therapeutic option for selected patients with end stage lung disease. Long-term survival is limited by chronic rejection manifest as bronchiolitis obliterans syndrome (BOS). The aspiration of gastric ... Full text Link to item Cite

Hepatitis C transmission, prevention, and treatment knowledge among patients with HIV.

Journal Article South Med J · July 2010 OBJECTIVE: Liver disease associated with hepatitis C virus (HCV) is a serious cause of mortality among people living with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) (PLWHA). Little is known about the HCV knowledge of PLWHA. ... Full text Link to item Cite

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Journal Article Gastroenterology · July 2010 BACKGROUND & AIMS: We recently identified a polymorphism upstream of interleukin (IL)-28B to be associated with a 2-fold difference in sustained virologic response (SVR) rates to pegylated interferon-alfa and ribavirin therapy in a large cohort of treatmen ... Full text Link to item Cite

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.

Journal Article Gastroenterology · June 2010 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infections are treated with pegylated interferon and ribavirin (PEG-IFN/RBV), which is effective in less than 50% of those infected with HCV genotype 1. Genome-wide association studies have l ... Full text Link to item Cite

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Journal Article Hepatology · June 2010 UNLABELLED: Recently, genetic polymorphisms occurring in the interferon (IFN)-lambda gene region were associated with response to IFN-based treatment of hepatitis C infection. Both infection with the hepatitis C virus and IFN therapy are associated with de ... Full text Link to item Cite

Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group.

Journal Article Pediatr Blood Cancer · May 2010 Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term l ... Full text Link to item Cite

Telaprevir in the treatment of patients with genotype 1 hepatitis C

Journal Article Gastroenterology and Hepatology · May 1, 2010 Cite

Telaprevir for previously treated chronic HCV infection.

Journal Article N Engl J Med · April 8, 2010 Featured Publication BACKGROUND: Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment. METHODS: We randomly assigned patients with HCV genotype 1 ... Full text Link to item Cite

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

Journal Article Nature · March 18, 2010 Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and i ... Full text Link to item Cite

Ortho Clinical Diagnostics: Scientific knowledge influences our way of life

Journal Article Revue Francophone des Laboratoires · January 1, 2010 Full text Cite

Editorial: Accreditation: The Revue Francophone des Laboratoires seeks dialogue

Journal Article Revue Francophone des Laboratoires · January 1, 2010 Full text Cite

The use of mind-body medicine and prayer among adult patients with chronic hepatitis C.

Journal Article Gastroenterol Nurs · 2010 The use of mind-body medicine by patients with chronic hepatitis C has not been reported. The prevalence and reasons for using mind-body medicine and prayer among a cohort of patients with chronic hepatitis C are described. Use of mind-body medicine and pr ... Full text Link to item Cite

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Journal Article Nature · September 17, 2009 Featured Publication Chronic infection with hepatitis C virus (HCV) affects 170 million people worldwide and is the leading cause of cirrhosis in North America. Although the recommended treatment for chronic infection involves a 48-week course of peginterferon-alpha-2b (PegIFN ... Full text Link to item Cite

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Journal Article N Engl J Med · August 6, 2009 Featured Publication BACKGROUND: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. METHODS: At 118 sit ... Full text Link to item Cite

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Journal Article N Engl J Med · April 30, 2009 Featured Publication BACKGROUND: Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV R ... Full text Link to item Cite

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

Journal Article Clin Gastroenterol Hepatol · February 2009 BACKGROUND & AIMS: Pegylated interferon alfa-2a/2b is used in combination with ribavirin to treat patients with chronic hepatitis C (CHC), although many do not achieve a sustained virologic response (SVR). Albinterferon alfa-2b, a recombinant protein consi ... Full text Link to item Cite

Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C.

Journal Article Psychosomatics · 2009 BACKGROUND: Chronic hepatitis C (CHC) is the most common blood-borne infection in the United States, but little is known about illness uncertainty in these patients. OBJECTIVE: The authors examined the constructs of illness uncertainty. METHOD: In this cro ... Full text Link to item Cite

Disparities in liver transplantation before and after introduction of the MELD score.

Journal Article JAMA · November 26, 2008 CONTEXT: In February 2002, the allocation system for liver transplantation became based on the Model for End-Stage Liver Disease (MELD) score. Before MELD, black patients were more likely to die or become too sick to undergo liver transplantation compared ... Full text Link to item Cite

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Journal Article J Hepatol · August 2008 Featured Publication BACKGROUND/AIMS: This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin. METHODS: Twelve treatment-naïve patients with chronic genotype 1 hepatitis C virus infection received tela ... Full text Link to item Cite

Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia.

Journal Article J Clin Gastroenterol · August 2008 GOALS: We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia. BACKGROUND: Gastroesophageal variceal ... Full text Link to item Cite

In the clinic. Hepatitis C.

Journal Article Ann Intern Med · June 3, 2008 Featured Publication Chronic hepatitis C virus (HCV) infection is the most common blood-borne infection in the United States, with an estimated overall prevalence of 3.2 million persons (1.3%) and prevalence peaks between age 40 to 49 years (1). The worldwide prevalence of HCV ... Full text Link to item Cite

Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era.

Journal Article Liver Transpl · February 2008 Featured Publication In the current system of allocation, patients awaiting orthotopic liver transplantation (OLT) remain at risk of developing de novo hepatocellular carcinoma (HCC) and removal from the waiting list. Using the United Network for Organ Sharing database, we cal ... Full text Link to item Cite

Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection

Journal Article Gastroenterology and Hepatology · January 1, 2008 Cite

Severity of Clostridium difficile-associated diarrhea in solid organ transplant patients.

Journal Article Transpl Infect Dis · December 2007 Clostridium difficile-associated diarrhea (CDAD) has a wide spectrum of disease severity. Studies have implicated immunosuppressants as a risk factor for severe disease. We hypothesized that solid organ transplant (SOT) patients with CDAD would be at great ... Full text Link to item Cite

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus.

Journal Article Hepatology · November 2007 UNLABELLED: CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-p ... Full text Link to item Cite

Factors Influencing Participation in Hepatitis C Research Trials

Conference American Journal of Gastroenterology · September 2007 Full text Cite

The Readability of Hepatitis C Health Education Materials

Conference American Journal of Gastroenterology · September 2007 Full text Cite

Hepatitis C - Current advances in therapy

Journal Article Practical Gastroenterology · August 1, 2007 This article summarizes current treatment recommendations and discusses alternative approaches to therapy in patients with hepatitis C. ... Cite

Immunosuppressive Medications

Journal Article · January 1, 2007 Full text Cite

Treatment of hepatitis C in special populations.

Journal Article Clin Liver Dis · November 2006 Featured Publication Hepatitis C virus (HCV) is a major cause of liver disease worldwide and is the most common chronic blood-borne infection in the United States. Experience has shown that the epidemiology and the response to treatment of HCV vary in certain patient groups. D ... Full text Link to item Cite

Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis.

Journal Article J Hepatol · October 2006 BACKGROUND/AIMS: Azathioprine is a key drug in the management of autoimmune hepatitis (AIH), with effects mediated via conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP), the latter controlled by thiopurine methyltransferase (TPMT). Our ... Full text Link to item Cite

Sertaline for the Prevention of Depression with HCV Therapy

Conference American Journal of Gastroenterology · September 2006 Full text Cite

Severity of Clostridium difficile Associated Diarrhea in Solid-Organ Transplant Patients

Conference American Journal of Gastroenterology · September 2006 Full text Cite

The impact of race and ethnicity on the treatment of hepatitis C disease

Journal Article Current Hepatitis Reports · August 1, 2006 Hepatitis C is the most common blood-borne infection in the United States and the most common cause of liver-related morbidity and mortality. There are significant racial/ethnic disparities in the epidemiology, natural history, and treatment outcomes of he ... Full text Cite

Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection.

Journal Article J Viral Hepat · May 2006 Given that the complications of hepatitis C are due to fibrosis, we hypothesized that the antifibrotic effects of interferon gamma on stellate cells would lead to beneficial effects in patients with hepatitis C. Thus, we evaluated the safety and efficacy o ... Full text Link to item Cite

Diagnosis and treatment of chronic hepatitis C infection.

Journal Article BMJ · April 29, 2006 Featured Publication Full text Link to item Cite

Clinical utilization of digital rectal examination and fecal occult blood testing upon hospital admission.

Journal Article J Clin Gastroenterol · 2006 GOALS: The objective of our investigation was to examine the clinical utilization of digital rectal examination (DRE) and fecal occult blood testing (FOBT) at hospital admission. BACKGROUND: DRE at the time of hospital admission is frequently accompanied b ... Full text Link to item Cite

Treatment of hepatitis C in special populations.

Journal Article Clin Liver Dis · November 2005 Treatment options for hepatitis C virus (HCV) infection have improved significantly in recent years, however, treatment recommendations came from large clinical trials of highly selected patient populations. HCV infection has increased prevalence in Africa ... Full text Link to item Cite

Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection.

Journal Article Transplantation · July 15, 2005 Featured Publication BACKGROUND: Chronic hepatitis C virus (HCV) infection is the most common indication for orthotopic liver transplantation (OLT) in the United States. Recent studies from selected centers have suggested that older donor age is associated with worse outcomes ... Full text Link to item Cite

Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus.

Journal Article Clin Transplant · April 2005 Sirolimus is emerging as a popular immunosuppressive agent for patients undergoing solid organ and pancreatic cell transplantation. Here, we report the clinical courses of three patients receiving sirolimus who developed aggressive gastroduodenal ulcer dis ... Full text Link to item Cite

Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.

Journal Article Am J Gastroenterol · February 2005 OBJECTIVES: In hepatitis C virus (HCV)-infected patients receiving pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy, anemia is a well-known side effect. The purpose of this study was to describe the time course and extent of hemoglobin (H ... Full text Link to item Cite

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Journal Article N Engl J Med · May 27, 2004 Featured Publication BACKGROUND: Several small studies have reported a lower response rate to interferon alfa among black patients with chronic hepatitis C infection than among white patients. The increased prevalence of infection with hepatitis C virus (HCV) genotype 1, which ... Full text Link to item Cite

A case of electrical storm in a liver transplant patient.

Journal Article Transplant Proc · June 2003 Electrical storm has not been well described in liver transplant patients. We present a case of sympathetically mediated recurrent ventricular fibrillation in a young patient transplanted for acute Wilson's disease. This case highlights the role of the sym ... Full text Link to item Cite

De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant.

Journal Article Am J Transplant · May 2003 Orthotopic liver transplantation is the only definitive therapeutic option in patients with primary sclerosing cholangitis (PSC) and end-stage liver disease. However, PSC recurs in up to 20% of patients transplanted for this indication. To date, no patient ... Full text Link to item Cite

An examination of factors predicting prioritization for liver transplantation.

Journal Article Liver Transpl · October 2002 With the recent transition of the liver transplant allocation system to the Model for End-Stage Liver Disease, a major change is its reliance entirely on objective criteria. In previous reports, potential donor families and members of the transplant commun ... Full text Link to item Cite

A survey of current liver biopsy practice patterns.

Journal Article J Clin Gastroenterol · July 2002 GOALS: To survey clinicians regarding current liver biopsy practice patterns. BACKGROUND: Although the hepatitis C epidemic has increased the proportion of hepatology in general gastroenterology practice, many clinicians express concern regarding the risks ... Full text Link to item Cite

Immunolocalization of beta-D-glucans, pectins, and arabinogalactan-proteins during intrusive growth and elongation of nonarticulated laticifers in Asclepias speciosa Torr.

Journal Article Planta · July 2002 Nonarticulated laticifers are latex-containing cells that elongate indefinitely and grow intrusively between the walls of meristematic cells. To identify biochemical mechanisms involved in the growth of nonarticulated laticifers, we have analyzed the distr ... Full text Link to item Cite

Acute HCV: the early bird catches the virus.

Journal Article Gastroenterology · April 2002 Full text Link to item Cite

A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection.

Journal Article J Clin Gastroenterol · March 2002 GOAL: To assess the number of chronic hepatitis C patients eligible for therapy. BACKGROUND: Recent studies have shown improved response rates to treatment of chronic hepatitis C infection. However, treatment with interferon alfa has major side effects, an ... Full text Link to item Cite

A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis.

Journal Article Am J Gastroenterol · May 2001 OBJECTIVES: The ileal pouch anal anastomosis is a safe and effective procedure but is also associated with pouchitis, small bowel obstruction, and incontinence. We prospectively evaluated the health-related quality of life using generic and disease-specifi ... Full text Link to item Cite

Reducing medication regimen complexity: a controlled trial.

Journal Article J Gen Intern Med · February 2001 OBJECTIVE: To determine if a visual intervention (medication grid) delivered to physicians can reduce medication regimen complexity. DESIGN: Nonrandomized, controlled trial. SETTING: Veterans Affairs medical center. PATIENTS/PARTICIPANTS: Eight hundred thi ... Full text Link to item Cite

Localization of cell wall polysaccharides in nonarticulated laticifers of Asclepias speciosa Torr.

Journal Article Protoplasma · 2001 Asclepias speciosa Torr. has latex-containing cells known as nonarticulated laticifers. In stem sections of this species, we have analyzed the cell walls of nonarticulated laticifers and surrounding cells with various stains, lectins, and monoclonal antibo ... Full text Link to item Cite

The natural history of hepatitis C viral infection.

Journal Article Semin Gastrointest Dis · April 2000 Although early data suggested that chronic hepatitis C virus infection carried little risk, studies with longer duration of infection have reported concerning results. Of patients with acute infection, approximately 80% will develop chronic infection. The ... Link to item Cite

The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.

Journal Article Virology · October 15, 1996 Antisera to 21 synthetic peptides containing hydrophilic sequences of simian immunodeficiency virus strain mac251 (SIVmac251) gp120 and gp32 were tested for the ability to neutralize SIVmac251. Goat antisera raised to peptides SP-1 and SP-1V containing the ... Full text Link to item Cite

Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Journal Article J Virol · October 1992 Twelve synthetic peptides containing hydrophilic amino acid sequences of human T-cell lymphotropic virus type I (HTLV-I) envelope glycoprotein were coupled to tetanus toxoid and used to raise epitope-specific antisera in goats and rabbits. Low neutralizing ... Full text Link to item Cite